SELLAS Life Sciences (SLS) Change in Accured Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Change in Accured Expenses data on file, last reported at -$1.3 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 56.34% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was -$310000.0, a 92.32% increase from a year earlier, with the FY2025 full-year figure at -$1.9 million, up 11.13% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.3 million, down from $545000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for SLS reached as high as $1.7 million in Q4 2022 and fell as low as -$2.9 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$17294.1 across 5 years, with a median of $196000.0 in 2023.
• Across the five-year window, Change in Accured Expenses surged 2713.11% in 2022 and sank 631.63% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.7 million in 2022, then slumped by 53.03% to $806000.0 in 2023, then plunged by 102.98% to -$24000.0 in 2024, then surged by 2370.83% to $545000.0 in 2025, then plunged by 331.93% to -$1.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$1.3 million in Q1 2026, $545000.0 in Q4 2025, and $897000.0 in Q3 2025.